TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Journal

GLP-1 and Tirzepatide Journal

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

The journal covers what is changing in the tirzepatide market: compounding rules, prices and new clinical evidence. It has 33 articles, each built on primary sources with a section on what the evidence does not settle. The two newest, from November 20, 2026, count the price disclosures of 68 programs and compare Collective with Mondae.

Answer last reviewed:

New in November 2026

What this section is for

The rest of the site answers questions that change slowly: what a drug costs, what a trial found, how to check a pharmacy. The journal follows what moves. The biggest open regulatory question is the FDA’s April 2026 proposal to keep tirzepatide, semaglutide and liraglutide off the 503B bulks list; the comment period closed on July 30, 2026, and a Federal Register search on November 9, 2026 found no final decision. On the commercial side, brand self-pay prices and the channels that sell them keep shifting, and compounded prices moved again in November.

Every article cites the primary source (the agency notice, the trial publication or registry entry, or the seller’s own page with the date we read it) and says plainly what the evidence does not establish.

How tirzepatide compounding became a regulatory question
2022Tirzepatide added to the F2024-10FDA declared the tirzepati2025-02FDA declared the semagluti2025-09-16FDA issued 55+ warning let2026-02-09Novo Nordisk sued Hims & H2026-03-03FDA released 30 further wa2026-03-09Hims & Hers settled with N2026-04-30FDA proposed excluding tir2026-05-01Formal notice published at2026-06-26Comment period extended to2026-07-30Comment period closes
Show this figure as a table
Data table
DateEvent
2022Tirzepatide added to the F
2024-10FDA declared the tirzepati
2025-02FDA declared the semagluti
2025-09-16FDA issued 55+ warning let
2026-02-09Novo Nordisk sued Hims & H
2026-03-03FDA released 30 further wa
2026-03-09Hims & Hers settled with N
2026-04-30FDA proposed excluding tir
2026-05-01Formal notice published at
2026-06-26Comment period extended to
2026-07-30Comment period closes
Every event above links to the agency's own document, not to coverage of it.

NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).

Questions readers actually ask

How often does the journal publish?

When there is something sourced to say. We do not publish on a schedule, because a publication calendar produces articles whether or not the evidence has moved.

Why are some articles missing?

Three are commissioned but, and stay noindexed until they carry content worth reading. The retatrutide piece waits on primary-source confirmation of phase 3 figures.

Cite this pageCC BY 4.0

Tirzepatide Ranked. “GLP-1 and Tirzepatide Journal.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/journal/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error
Comparing 0 of 4